Physician profile
Andrea Duchini
NPI 1710067053
$127,011.08
in general payments reported to CMS, 2019-2025
33 companies · $946 in 2025
The $946 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $22K · 2021: $19K · 2022: $15K · 2023: $16K · 2024: $14K · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $4,459 · Food and Beverage: $3,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,020.00 |
| Travel and Lodging | $4,459.04 |
| Food and Beverage | $3,079.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $108,820.52 | 2019-2025 | Epclusa, Livdelzi |
| Abbvie INC. | $14,134.52 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,355.18 | 2019-2025 | Xifaxan, Trulance |
| Intra-Sana Laboratories | $464.44 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $337.68 | 2019-2025 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $265.73 | 2022-2025 | Terlivaz |
| Mirum Pharmaceuticals, INC. | $182.71 | 2025 | Livmarli |
| Shionogi INC | $166.21 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $137.16 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $121.86 | 2024 | Andexxa |
| Fujifilm Healthcare Americas Corporation | $121.44 | 2022 | |
| Ferring Pharmaceuticals INC. | $105.08 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $95.53 | 2021-2022 | |
| Dynavax Technologies Corporation | $89.63 | 2022 | |
| Pfizer INC. | $89.43 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $71.13 | 2020-2022 | |
| Novo Nordisk INC | $46.44 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $45.49 | 2021-2022 | |
| Madrigal Pharmaceuticals | $43.84 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $42.62 | 2022-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $40.82 | 2021-2024 | Eohilia |
| Olympus America INC. | $30.55 | 2019 | |
| Siemens Medical Solutions USA, INC. | $22.09 | 2020 | |
| Daiichi Sankyo INC. | $21.97 | 2020 | |
| Apollo Endosurgery US INC | $20.75 | 2019 | |
| Aimmune Therapeutics, INC. | $20.50 | 2025 | Zenpep |
| Vivus LLC | $20.36 | 2022 | |
| Celltrion USA INC. | $20.35 | 2025 | Vegzelma |
| Orphalan INC | $17.12 | 2024 | Cuvrior |
| Alexion Pharmaceuticals, INC. | $16.55 | 2019 | |
| Ucb, INC. | $15.56 | 2020 | |
| Dova Pharmaceuticals | $14.55 | 2019 | |
| Allergan, INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Duchini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.